Market Cap
$884.2M
TBPH
Theravance Biopharma, Inc.
—
Market cap$884.2M
ConsensusHold
12-mo target$17.67 (+3.7%)
▲ Bullish
Analyst conviction 6/10
Insider Selling Cluster (2 insiders)High Impact Filing (7/10) Biotech & Drug Discovery
Snapshot
The big-picture read on TBPH right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Buy (55%)
SEC Reports
8
Price chart
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 24, 2026 listing_status
Delisted: TBPH — removed from the Nasdaq symbol directory
Theravance Biopharma, Inc. - Ordinary Shares
Sep 23, 2026 Insider
Farnum Rhonda disposed of 124,414 shares
SVP, COMM & MEDICAL AFFAIRS
Sep 23, 2026 Insider
Farnum Rhonda disposed of 89,062 shares
SVP, COMM & MEDICAL AFFAIRS
Sep 23, 2026 Insider
Aug 25, 2026 SEC Farnum Rhonda disposed of 150,000 shares
SVP, COMM & MEDICAL AFFAIRS
Theravance Biopharma filed a DEFA14A (additional definitive proxy soliciting material) on August 25, 2026, making availa
DEFA14A — Impact 4/10
Theravance Biopharma (TBPH) is being acquired by Zymeworks (ZYME) for $17.00 per share in cash plus one CVR per share, w
DEFM14A — Impact 7/10
Theravance Biopharma (TBPH) filed a preliminary proxy statement (PREM14A) for an extraordinary general meeting to approv
PREM14A — Impact 7/10
Analyst ratings buy % -28.6%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
55% rate it Buy or better · 11 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Jul 7, 2026 | HC Wainwright & Co. | DOWNGRADE | Neutral | 43% |
| Jun 29, 2026 | Jones Trading | DOWNGRADE | Hold | 51% |
| Jun 29, 2026 | BTIG | DOWNGRADE | Neutral | 53% |
| Apr 7, 2026 | B. Riley Securities | MAINTAIN | Neutral | 54% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 2 | 4 | 5 | 0 | 0 | 55% | |
| Aug 1, 2026 | 2 | 4 | 5 | 0 | 0 | 55% | |
| Jul 1, 2026 | 2 | 5 | 4 | 0 | 0 | 64% | |
| Jun 1, 2026 | 3 | 5 | 4 | 0 | 0 | 67% | |
| May 1, 2026 | 3 | 5 | 4 | 0 | 0 | 67% | |
| Apr 1, 2026 | 3 | 5 | 5 | 0 | 0 | 62% | |
| Mar 1, 2026 | 4 | 6 | 3 | 0 | 0 | 77% | |
| Feb 1, 2026 | 4 | 6 | 3 | 0 | 0 | 77% |
Price targets
Where 3 covering analysts think TBPH trades over the next 12 months.
$17.67 +3.7% upside Hold
Current$17.03 Low$17.00 Median$17.00 High$19.00 3 analysts
$17.00$19.00
Analyst rating Hold· 3.0/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
8 SEC filing reports analyzed · 4 bullish, 1 bearish, 1 mixed, 2 neutral · avg impact 5.9/10.
NEUTRALDEFA14A4/10
Theravance Biopharma filed a DEFA14A (additional definitive proxy soliciting material) on August 25,
Aug 25, 2026
BULLISHDEFM14A7/10
Theravance Biopharma (TBPH) is being acquired by Zymeworks (ZYME) for $17.00 per share in cash plus
Aug 21, 2026
BULLISHPREM14A7/10
Theravance Biopharma (TBPH) filed a preliminary proxy statement (PREM14A) for an extraordinary gener
Aug 11, 2026
BULLISH8-K7/10
Theravance Biopharma reported Q2 2026 earnings with no analyst consensus provided for the current pe
Aug 10, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 24, 2026
listing_status
Delisted: TBPH — removed from the Nasdaq symbol directory
Theravance Biopharma, Inc. - Ordinary Shares
Aug 14, 2026
short_interest_report
Short Interest: TBPH down 59% to 1.7M shares
Settlement 2026-08-14 | Days to cover: 2.51 | ≈3.30% of shares outstanding (est.)
Aug 5, 2026
earnings_calendar
TBPH Q2 2026 Earnings Scheduled — 2026-08-05
May 23, 2026
Clinical Trial
A Study of TD-1211 in Subjects With Opioid-Induced Constipation (OIC)
Phase Phase 2 — COMPLETED
May 23, 2026
Clinical Trial
A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of TD-1211 in Subjects With Opioid-Induced Constipation
Phase Phase 2 — COMPLETED
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $0.20 | $0.20–$0.20 | 359.8% | +0.0% | — | $0.0B | 1 |
| Next Q | $-0.08 | $-0.08–$-0.08 | -235.6% | +0.0% | — | $0.0B | 1 |
| Current FY | $0.21 | $0.21–$0.21 | 241.8% | +0.0% | — | $0.1B | 1 |
| Next FY | $1.27 | $0.80–$1.75 | 507.1% | +59.4% | — | $0.1B | 2 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $0.200 | — |
| 7d ago | $0.200 | — |
| 30d ago | $0.200 | — |
| 60d ago | $0.200 | — |
| 90d ago | $0.200 | — |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
9 insiders, 50 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 23, 2026 | Farnum Rhonda | SVP, COMM & MEDICAL AFFAIRS | D | 124,414 | — | — |
| Sep 23, 2026 | Farnum Rhonda | SVP, COMM & MEDICAL AFFAIRS | D | 89,062 | — | — |
| Sep 23, 2026 | Farnum Rhonda | SVP, COMM & MEDICAL AFFAIRS | D | 150,000 | — | — |
| Sep 23, 2026 | Grimaud Brett A. | SVP, GEN COUNSEL AND SECRETARY | D | 223,917 | — | — |
| Sep 23, 2026 | Grimaud Brett A. | SVP, GEN COUNSEL AND SECRETARY | D | 107,812 | — | — |
| Sep 23, 2026 | Miller Aine | SVP, DEV & HEAD OF IRE OFFICE | D | 93,108 | — | — |
| Sep 23, 2026 | Grimaud Brett A. | SVP, GEN COUNSEL AND SECRETARY | D | 23,439 | — | — |
| Sep 23, 2026 | Miller Aine | SVP, DEV & HEAD OF IRE OFFICE | D | 96,718 | — | — |
| Sep 23, 2026 | Miller Aine | SVP, DEV & HEAD OF IRE OFFICE | D | 37,500 | — | — |
| Sep 23, 2026 | Sawaf Aziz | SVP & CHIEF FINANCIAL OFFICER | D | 204,966 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for TBPH.
Shares short
1,686,673
Settlement Sep 15, 2026
Change vs prior
+4.2%
Semi-monthly cycle
Days to cover
4.5
At avg daily volume
Of shares outstanding
≈3.3%
Estimate — not % of float
All TBPH filing & press-release reports (8)
- DEFA14A reportAug 25, 2026
- DEFM14A reportAug 21, 2026
- PREM14A reportAug 11, 2026
- 8-K reportAug 10, 2026
- 8-K reportJun 29, 2026
- 8-K reportJun 24, 2026
- 8-K reportMay 7, 2026
- 8-K reportMar 3, 2026